TD Private Client Wealth’s Crinetics Pharmaceuticals CRNX Stock Holding History

TD Private Client Wealth’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19	Closed	-$690	–	1716
2026 Q1	$690	Buy	+19	New	+$849	﹤0.01%	1449
2025 Q2	–	Sell	-48	Closed	-$1.61K	–	1439
2025 Q1	$1.61K	Buy	+48	New	+$1.79K	﹤0.01%	1223

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Private Client Wealth's CRNX Position: Q2 2026 in Review

TD Private Client Wealth sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 19 shares — an estimated $690 sold.

TD Private Client Wealth first reported a position in CRNX in Q1 2025 and held it in 2 quarters. The position peaked at $1.61K in Q1 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

TD Private Client Wealth reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
TD Private Client Wealth sold 19 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $690.
TD Private Client Wealth first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 2 quarters.
TD Private Client Wealth's Crinetics Pharmaceuticals position peaked at $1.61K in Q1 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.